Comparing two types of radiation for soft tissue sarcoma
Part of Cancer clinical trials.
This trial tests a newer way of giving radiation (spatially fractionated) compared to standard radiation for people with large soft tissue sarcomas. It aims to see if the new method works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with soft tissue sarcoma (a type of cancer in connective tissues).
- Your tumor is at least 5 centimeters (about 2 inches) in diameter.
- You are already receiving or planning to receive systemic treatment (like chemotherapy) as recommended by your cancer care team.
- You are able to take care of yourself (performance status 0-2, meaning you are up and about more than half the day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation therapy and an immunotherapy approach (called PraG) for people with advanced soft tissue sarcoma that can't be removed by surgery or has spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests whether adding immunotherapy drugs (anlotinib and penpulimab) to radiation before surgery can help treat soft tissue sarcoma—a type of cancer in muscles, fat, or connective tissue. The goal is to shrink the tumor and improve surgical outcomes.
This trial studies a high-dose, shortened course of proton beam radiation for people with soft tissue sarcoma that cannot be removed by surgery. It aims to improve tumor control while reducing side effects.
This trial tests if giving a short course of radiation therapy combined with immunotherapy before surgery can improve outcomes for people with soft tissue sarcoma in the belly or pelvis. It is for patients whose tumors are hard to remove completely without this pre-treatment.
This trial tests a combination of targeted therapy, chemotherapy, and radiation for advanced soft tissue sarcoma that has not responded to standard treatment. It aims to see if the combination can help patients live longer or shrink their tumors.
This trial tests two injectable medications (OVV-01 and AK112) combined together to treat advanced soft tissue sarcoma—a cancer that has spread or cannot be surgically removed—in patients whose previous treatments have failed. The goal is to see if injecting these drugs directly into tumors can help shrink them and improve outcomes.
Hear when a new Soft Tissue Sarcoma (STS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.